Pre-Exposure Prophylaxis for Homeless Youth: A Rights-Based Perspective

A community perspective on pre-exposure prophylaxis

The history of pre-exposure prophylaxis (PrEP) is notable for being a community rather than industry-driven development. This talk will review this history, covering factors that include community demand, study results, regulatory challenges, commercial interests and practical issues of public health. It will also look at some of the controversies that appear to limit broader access, and import...

A Review of HIV Pre-Exposure Prophylaxis: The Female Perspective

When taken consistently, pre-exposure prophylaxis (PrEP) against human immunodeficiency virus (HIV) with once daily tenofovir disoproxil fumarate-emtricitabine (TDF-FTC) has been shown to safely reduce the incidence of HIV infection in high-risk individuals by more than 90%. Yet, according to the Centers for Disease Control and Prevention, there were about 2.1 million new cases of HIV reported ...

Pre-exposure Prophylaxis (PrEP)

In 2012, the US Food and Drug Administration (FDA) approved Truvada to be used as PrEP by HIV negative people who are at high risk of sexually acquired HIV infection. The US Centre for Disease Control has since developed guidelines and recommended PrEP be used by people at high risk of HIV acquisition via sexual transmission or injection drug use (http://www.cdc.gov/hiv/prevention/research/prep/).

Annotated Bibliography: Pre-Exposure Prophylaxis

Pre-Exposure Prophylaxis for HIV Prevention.

c ase vignet tes The first patient, a 46-year-old sexually active man who has sex with men, presents for routine primary care. He lives in New York City and reports that he is in a long-term, stable, open relationship with a male partner and that he has had multiple recent sexual encounters with acquaintances. A recent HIV test was negative. He has seasonal allergies, for which he occasionally ...